NCT05827614
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05827614
Title Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy, in Subjects With Tumors With Oncogene Amplifications (POTENTIATE)
Acronym POTENTIATE
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Boundless Bio
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UCLA Medical Center Los Angeles California 90095 United States Details
Sarcoma Oncology Santa Monica California 90403 United States Details
HealthONE Denver Colorado 80218 United States Details
Florida Cancer Specialists Lake Mary Florida 32746 United States Details
The University of Kansas Fairway Kansas 66205 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
START Midwest Grand Rapids Michigan 49546 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
SCRI Oncology Partners Nashville Tennessee 37203 United States Details
MD Anderson Cancer Center Houston Texas 77054 United States Details
NEXT Oncology - Dallas Irving Texas 75039 United States Details
NEXT Oncology San Antonio Texas 78229 United States Details
NEXT Oncology Fairfax Virginia 22031 United States Details
University of Washington, Fred Hutchinson Cancer Center Seattle Washington 98109 United States Details
University of Wisconsin Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field